Cargando…

Phenotypic consensus markers for plasma cell myeloma

Detalles Bibliográficos
Autor principal:	Hur, Mina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2012
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538791/ https://www.ncbi.nlm.nih.gov/pubmed/23319998 http://dx.doi.org/10.5045/kjh.2012.47.4.239

Ejemplares similares

Mac-2 Binding Protein Glycosylation Isomer: Emerging Non-Invasive Serum Marker for Liver Fibrosis
por: Cho, Sun Young, et al.
Publicado: (2018)

Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
por: Fernández de Larrea, Carlos, et al.
Publicado: (2021)

Variant Burkitt-type translocation (8;22)(q24;q11) in plasma cell myeloma
por: Kim, Hanah, et al.
Publicado: (2011)

It is time for consensus on ‘consensus statements’
por: Blazey, Paul, et al.
Publicado: (2022)

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2020)

RBO with no consensus
por: Camanho, Gilberto Luis
Publicado: (2016)

Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells
por: Kassambara, Alboukadel, et al.
Publicado: (2013)

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2021)

Oncogene addiction to c-MYC in myeloma cells
por: Holien, Toril, et al.
Publicado: (2012)

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
por: Moreau, Philippe, et al.
Publicado: (2019)

Giant multinucleated plasma cells in relapsed plasma cell myeloma
por: Ghattas, Sylvia, et al.
Publicado: (2020)

Neutrophil Gelatinase-Associated Lipocalin as a Promising Novel Biomarker for Early Detection of Kidney Injury
por: Cho, Sun Young, et al.
Publicado: (2018)

Expanded Impacts of Platelet Functions: Beyond Hemostasis and Thrombosis
por: Cho, Sun Young, et al.
Publicado: (2019)

Advances in Automated Urinalysis Systems, Flow Cytometry and Digitized Microscopy
por: Cho, Sun Young, et al.
Publicado: (2019)

Hepcidin and Neutrophil Gelatinase-Associated Lipocalin as a Biomarker for Acute Kidney Injury Linked Iron Metabolism
por: Cho, Sun Young, et al.
Publicado: (2020)

Hepcidin-25 as a Novel Kidney Biomarker for Cardiac Surgery-Associated Acute Kidney Injury
por: Cho, Sun Young, et al.
Publicado: (2021)

Quantum Leap and Future Contribution of Annals of Laboratory Medicine
por: Kim, Young Jin, et al.
Publicado: (2022)

New Issues With Neutrophil Gelatinase-associated Lipocalin in Acute Kidney Injury
por: Cho, Sun Young, et al.
Publicado: (2023)

Myeloma therapy: pursuing the plasma cell
por: Cavenagh, J
Publicado: (2010)

Extracellular crystals in plasma cell myeloma
por: Brown, Jacqueline T., et al.
Publicado: (2014)

Plasma Cell Myeloma Masquerading as Scleromyxedema
por: Victor, Varun, et al.
Publicado: (2019)

Consensus Science and the Peer Review
por: Barrio, Jorge R.
Publicado: (2009)

Hereditary Angioedema Consensus 2010
por: Bowen, Tom
Publicado: (2010)

Medical Literature and Scientific Consensus
por: Sop, Ashok K
Publicado: (2015)

There is no consensus that overcomes common sense()
por: Camanho, Gilberto Luis
Publicado: (2014)

Consensus, the College and Cerebrovascular Medicine
por: Bamford, J M
Publicado: (1995)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Myeloma research on the move
por: Ludwig, Heinz
Publicado: (2021)

Biological Insights into Myeloma and Other B Cell Malignancies
por: Fulciniti, Mariateresa, et al.
Publicado: (2016)

Laboratory Medicine 2014
por: Hur, Mina, et al.
Publicado: (2014)

Laboratory Medicine 2016
por: Hur, Mina, et al.
Publicado: (2016)

Experts’ consensus on the definition and management of high risk multiple myeloma
por: Marcon, Chiara, et al.
Publicado: (2023)

Concussion in sport: the consensus process continues
por: Schneider, Kathryn J, et al.
Publicado: (2022)

Hyperhaploid karyotypes in multiple myeloma
por: Sawyer, Jeffrey R., et al.
Publicado: (2017)

Enhancing ER stress in myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

Novel therapies for multiple myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

Latest Development in Multiple Myeloma
por: Imai, Yoichi
Publicado: (2020)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_uh6i36e0a33otjdfqhikem952o